FDA seeks mandatory supplement product listing; EU re-evaluates CBD Novel Food status
The US FDA's 2020 budget proposal indicates a push for mandatory dietary supplement product registration, while the EU reconsiders CBD's Novel Food classification based on historical use data. These regulatory shifts will redefine market entry barriers and compliance requirements for supplement brands.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington D.C., United States — The US Food and Drug Administration (FDA) has signalled its intent to pursue mandatory pre-market product registration for dietary supplements, as detailed in its proposed 2020 budget. Analysis by senior political advisors Tricia Knight and Peter Reinecke for the United Natural Products Alliance highlights the FDA's desire for statutory authority to require companies to list all dietary supplement products on the market. The FDA states current law lacks a clear mandate for product listing, hindering its ability to compile basic product information. This initiative aims to equip the FDA with the knowledge of newly introduced products, enabling swift action against potentially dangerous or illegal items, thereby enhancing transparency and supporting risk-based regulation.
Simultaneously, the European Industrial Hemp Association (EIHA) is challenging the European Commission's classification of Cannabidiol (CBD) as a Novel Food. EIHA has presented evidence to the Standing Committee on Plants, Animals, Food and Feed (PAFF Committee), asserting that hemp extracts containing naturally occurring CBD levels were consumed in the EU before May 1997. This historical use, if validated, would exempt CBD from Novel Food status, significantly streamlining market access for CBD-containing supplements within the EU. The current Novel Food regulation applies to any food not consumed to a significant degree in the EU prior to 15 May 1997.
In the Asia-Pacific region, Australian brand VÖOST is expanding its market footprint with a new sports nutrition range targeting male consumers. This strategic move aims to diversify its consumer base beyond its traditional younger female millennial demographic. VÖOST, which commands approximately 17% of Australia's A$65m effervescent vitamin sub-category, launched an orange-flavoured effervescent product under the 'VÖOST Performance' line. The new formulation includes B and C vitamins, magnesium, zinc, and calcium, available in 20 or 40-tablet packs, as revealed by co-founder Thomas Siebel to NutraIngredients-Asia. This demonstrates a focused approach to segment growth in a competitive market.
What this means for United Kingdom
UK supplement manufacturers and brand owners will face differing impacts based on their primary markets. Those exporting to the US must prepare for potential new compliance requirements and associated costs if FDA mandatory listing is enacted, including updating product databases and submitting comprehensive product information. For brands operating in the EU, a reclassification of CBD from Novel Food status would dramatically reduce the regulatory burden and cost-to-market for CBD products, currently a significant barrier. This could open new avenues for product innovation and market penetration in the UK post-Brexit, aligning with potential future UK regulatory reforms. Retailers should anticipate an influx of more accessible CBD products, requiring competitive pricing strategies and diversified stock units.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.